CD274 and neoplasm: Furthermore, in vivo research has demonstrated that concurrent use of oral chitosan-ID@NMs and PD-L1 checkpoint inhibitors can successfully suppress the primary tumor and strengthen the systemic anti-tumor immune response, resulting in long-lasting immune memory effects and averting tumor recurrence.